EYENOVIA INC

NASDAQ: EYEN (Eyenovia, Inc.)

Last update: 4 days ago, 5:53PM

1.06

0.23 (28.28%)

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Mixed
Biotechnology (Global) Bearish Mixed
Stock Eyenovia, Inc. Mixed Mixed

Similar Stocks

Stock Market Cap DY P/E P/B
-
BBIO 5 B - - -
AGIO 2 B - - 2.67
ABCL 1 B - - 0.950
ARQT 924 M - - 8.87
ALLO 524 M - - 1.09

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value

Ownership

Name Date Shares Held
Lasry Marc 31 Dec 2023 547,807
52 Weeks Range
0.501 - 3.64
High 12.00 (HC Wainwright & Co., 1,032.08%) Buy
Median 12.00 (1,032.08%)
Average 12.00 (1,032.08%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 16 May 2024 12.00 (1,032.08%) Buy 1.06
19 Mar 2024 12.00 (1,032.08%) Buy 1.18

No data within this time range.

Date Type Details
15 May 2024 Announcement Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
14 May 2024 Announcement Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th
25 Apr 2024 Announcement Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
08 Apr 2024 Announcement Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
03 Apr 2024 Announcement Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
18 Mar 2024 Announcement Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
13 Mar 2024 Announcement NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
11 Mar 2024 Announcement Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
05 Mar 2024 Announcement Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
04 Mar 2024 Announcement Formosa Pharmaceuticals and AimMax Therapeutics Receive FDA Approval for Clobetasol Propionate Ophthalmic Suspension 0.05%, for the Treatment of Post-Operative Inflammation and Pain Following Ocular Surgery

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data